HenryFungMD

PubMed

• 275 citations
  Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
  Caron A Jacobson, Julio C Chavez, Alison R Sehgal, Basem M William, Javier Munoz
  The Lancet. Oncology. 2022-01-01
• 35 citations
  Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.
  Emma C. Scott, Parameswaran Hari, Manish Sharma, Jennifer Le-Rademacher, Jiaxing Huang
  Biology of Blood and Marrow Transplantation. 2016-10-01
• 19 citations
  Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.
  Kazuhiro Mochizuki, Lijun Meng, Izumi Mochizuki, Qing Tong, Shan He
  Blood. 2016-06-23

Journal Articles

• Sequential Single-Agent Obatoclax Mesylate (GX15-070MS) Followed by Combination with Rituximab in Patients with Previously Untreated Follicular Lymphoma  
  Goy A, Berger M, Ford P, Feldman T, Mato A, Bejot C, Fung HC, Leukemia & Lymphoma, 1/22/2014
• Anger, Provider Responses, and Pain: Prospective Analysis of Stem Cell Transplant Patients  
  Gerhart JI, Sanchez Varela V, Burns JW, Hobfoll SE, Fung HC, Health Psychology, 1/18/2014
• Older patients with Myeloma Derive Similar Benefit from Autologous Transplantation  
  Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, Fung HC, et al, Biology of Blood and Marrow Transplantation, 1/18/2014
• Dosing Algorithm for Concomitant Administration of Sirolimus, Tacrolimus, and an Azole After Allogeneic Hematopoietic Stem Cell Transplantation  
  Peksa GD, Schultz K, Fung HC, Journal of Oncology Pharmacy Practice, 1/17/2014
• Clinical and Safety Profile of High-Dose Interleukin-2 (IL2) Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma  
  Clark JM, Kelley B, Titze J, Fung HC, Maciejewski J, Nathan S, Rich E, Basu S, Kaufman HL, Oncology, 1/1/2013
• Loss of CD26 Protease Activity in Recipient Mice During Hematopoietic Stem Cell Transplantation Results in Improved Transplant Efficiency  
  Yoo E, Paganessi LA, Alikhan WA, Paganessi EA, Hughes F, Fung HC, Rich E, Seong CM, Christopherson KW 2nd, Transfusion, 1/6/2012
• A Simplified Technique for Delivering Total Body Irradiation (TBI) with Improved dose Homogeneity  
  Yao R, Bernard D, Turian J, Abrams RA, Sensakovic W, Fung HC, Chu JC, Med Phys, 1/1/2012
• CD26 Protease Inhibition Improves Functional Response of Un-fractionated Mobilized Peripheral Blood Mononuclear Cells to CXCL12/SDF-1  
  Christopherson KW 2nd, Frank R, Jagan S, Paganessi LA, Rizman A, Gezer S, Gregory SA, Fung HC, Exp Hematol, 1/1/2012
• Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone, and Rituximab Followed by Yttium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front-...  
  Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O’Brien T, Gregory S, Clin Lymphoma Myeloma Leuk, 1/21/2011
• Strategies for Improving Transplant Efficiency in the Context of Cellular Therapeutics  
  A.M. Jimenez, Henry C Fung and Kent Chistopherson II, Transfusion, 1/1/2011
• Effective Mobilization of Hematopoietic Progenitor Cells in G-CSF Mobilization Defective CD26-/- Mice Through AMD3100-Induced Disruption of the CXCL12-CXCR4 Axis  
  Paganessi LA, Walker AL, Tan LL, Holmes I, Rich E, Fung HC, Christopherson KW 2nd, Exp Hematol, 1/1/2011
• In Vivo Expansion of the Megakaryocyte Progenitor Cell Population in Adult CD26-deficient Mice  
  Kidd S, Bueso-Ramos C, Jagan S, Paganessi LA, Boggio LN, Fung HC, Gregory SA, Christopherson KW 2nd, Experimental Hematology, 1/1/2011
• Induction Chemotherapy Before Autologous Stem Cell Transplantation for Patients with Symptomatic Plasma Cell Myeloma----does it matter?  
  Henry C Fung MBchB, FRCPE, Sunita Nathan MD, John J Maciejewski MD, PhD, Clinical Pharmacology: Advances and Applications, 1/1/2010
• High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapse after Allo-SCT in Multiple Myeloma: A Case Report  
  Tuncer HH, Gregory SA, Fung HC, Bone Marrow Transplant, 1/1/2010
• A Case of Myelodysplastic Syndrome in a Liver Transplant Patient  
  Potu R, Ahn J, Fung HC, Cohen S, Transplantation Proceedings, 1/1/2009
• Mesenchymal Stem Cells from the Wharton’s Jelly of Umbilical Cord Segments Provide Stromal Support for the Maintenance of Cord Blood Hematopoietic Stem Cells During Lo...  
  Bakhshi , Zabriskie RC, Bodie S, Kidd S, Ramin S, Paganesi LA, Gregory SA, Fung HC, Christopherson KW 2nd, Transfusion, 1/1/2008
• Idiopathic Hemophagocytic Syndrome with a Fulminant Clinical Couse  
  Khandelwal A, Shah NB, Eichenseer P, Welker M, Miller I, Nangia J, Farhat M, Gimelfarb A, Kasar M, Batus M, Gezer S, Shammo J, Gregory S, Fung H, Venugopal P, Clin Adv Hemaol Oncol, 1/1/2008
• Phase II trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients with Non-Hodgkin’s Lymphoma  
  Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ, Journal of clinical Oncology, 1/1/2008
• Use of Radioimmunotherapy in Stem Cell Transplantation and Post-Transplantation: Focus on Yttrium 90 Ibritumomab Tiuxetan  
  Molina A, Krishnan A, Fung H, Flinn I, Inwards D, Winter J, Nademanee A, Current Stem Cell Research & Therapy, 1/1/2007
• Tandem Autologous Stem Cell Transplantation for Patients with Primary Refractory or Poor Risk Recurrent Hodgkin Lymphoma  
  Fung HC, Stif P, Schriber J, Toor A, Smith E, Rodriguez T, Krishnan A, Molina A, Smith D, Ivers, Kogut N, Popplewell L, Rodriguez R, Somlo G, Forman SJ, Nademanee A, Biol Blood Marrow Transplant, 1/1/2007
• Crypt Loss is a Marker of Clinical Severity of Acute Gastrointestinal Graft-Versus-Host Disease  
  MelsonJ, Jakate S, Fung HC, Arai S, Keshavarzian A, American Journal of Hematology, 1/1/2007
• Maintenance Thalidomide Following Single Cycle Autologous Peripheral Blood Stem Cell Transplant in Patients with Multiple Myeloma  
  Sahebi F, Spielberger R, Kogut NM, Fung HC, et al., Bone Marrow Transplantation, 1/1/2006
• Does Follicularity in Large Cell Lymphoma Predict Outcome after Autologous Stem Cell Transplantation?  
  Krishnan A, Nademanee A, Fung HC, et al., Biol Blood Marrow Transplant, 1/1/2006
• Longitudinal Assessment of Hematopoietic Abnormalities after Autologous Hematopoietic Cell Transplantation for Lymphoma  
  Bhatia R, Van Heijzen K, Palmer A, Komiya A, Slovak ML, Chang KL, Fung HC, et al., Journal of Clinical Oncology, 1/20/2005
• A Phase I/II Trial of High Dose Yttrium Ibritumomab Tiuxetan in Combination with High-Dose Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant i...  
  Nademanee A, Forman S, Molina A, Fung HC, et al., Blood, 1/15/2005
• Join now to see all

Books/Book Chapters

• ACS Atlas of Clinical Oncology 
  Chapter: BMT for Hodgkin’s Disease and Malignant Lymphomas 
  Fung HC, Nademanee A, Forman SJEditors: Michael Grossbard.2001
• Allogeneic Stem Cell Transplantation 
  Chapter: Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia 
  Fung HC, Forman SJEditors: Hilard M. Lazarus and Mary J. Laughlin.
• Stress and Anxiety 
  Chapter: Chapter 1; Traumatic Stress, Health, and Strategies for Multi-Level Bio-Psycho-Social Interventions, 7-16 
  Hobfoll SE, Stevens NR, Gerhart JI, Clift AT, Vechiu C, Verela V, Anaya HA, Finigan M, Fung HCEditors: Kathleen A. Moore, Krzysztof Kaniasty, Petra Buchwald and Albert Sese.

Abstracts/Posters

• Graft Versus Host Disease Prophylaxis with a Bortezomib-Based Regimen without G-CSF Support for Patients Undergoing MUD Transplant: Evaluation of Engraftment Kinetics ...
  AM Jimenez, AD Moreno, J Maciejewski, A Dalovisio, D Katz, C Havey, N Merchant, HC Fung, S Nathan, Biology of Blood and Marrow Transplantation, 1/28/2015
• Severe Mucositis with Bendamustine Etoposide Ara-C and Melphalan (Be-EAM) As Conditioning Regimen in Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cel...
  S Nathan, AM Jimenez, AD Moreno, J Maciejewski, HC Fung, Biology of Blood and Marrow Transplant, 1/2/2015
• Evaluating Neutropenia Recovery in Patients Receiving Filgrastim on Day +5 Versus Day +10 Post Autologous Hematopoietic Stem Cell Transplant
  LM DiGrazia, M Janusek, K Schultz, L Geswein, HC Fung, Biology of Blood and Marrow Transplant, 1/2/2015
• Long-Term Follow-up and Experience with Donor Lymphocyte Infusion (DLI); Is It Time for a Paradigm Shift?
  NM Hossain, T Klumpp, J Ulicny, M Garner PL Kropf, KF Mangan, SK Barta, HC Fung, ME Martin, Biology of Blood and Marrow Transplant, 1/2/2015
• Trajectories of Distress in Hematopoietic Stem Cell Transplant Recipients
  Asvat Y, Gerhart J, Sokolovsky A, Hobfoll S, Fung HC, SBM Annual Meeting, 1/1/2015
• Posttraumatic Stress Symptoms Predict Impaired Neutrophil Recovery in Stem Cell Transplant
  SE Hobfoll, JI Gerhart, AK Zalta, K Wells, J Maciejewski, H Fung, Psycho-Oncology, 1/1/2015
• Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation
  M Sharma, MJ Zhang, X Zhong, MH Abidi, G Akpek, U Bacher, NS Callander, A Dispenzieri, CO Freytes, HC Fung, RP Gale, C Gasparetto, J Gibson, LA Holmberg, TL Kindwall-K..., Biology of Blood and Marrow Transplantation, 1/30/2014
• Anger, Provider Responses, and Pain: Prospective Analysis of Stem Cell Transplant Patients
  JI Gerhart, VS Varela, JW Burns, SE Hobfoll, HC Fung, American Psychological Association, 1/18/2014
• Dosing Algorithm for Concomitant Administration of Sirolimus, Tacrolimus, and an Azole after Allogeneic hematopoietic Stem Cell Transplantation
  GD Peksa, K Schultz, HC Fung, Journal of Oncology Pharmacy Practice, 1/17/2014
• Gastrointestinal Side Effects and Adequacy of Enteral Intake in Hematopoietic Stem Cell Transplant Patients
  M Walrath, C Bacon, S Foley, HC Fung, Nutrition in Clinical Practice, 1/16/2014
• Single-institution Experience with Autologous Stem Cell Transplants for Mantle Cell Lymphoma Patients
  Hossain NM, Zibelman MR, Khan N, Klumpp TR, Martin, ME, Millenson MM, Patel RD, Fisher RI, Fung HC, Kropf PL, Journal of Clinical Oncology, 1/1/2014
• A Phase 1 Dose-escalation Study of XmAb® 2513 in patients with Relapsed or Refractory Hodgkin Lymphoma
  A Kumara, KA Blum, HC Fung, MR Smith, PA Foster, A Younes, British Journal of Haematology, 1/1/2014
• Sequential Single-Agent Obatoclax Mesylate (GX15-070MS) Followed by Combination with Rituximab in Patients with Previously Untreated Follicular Lymphoma
  A Goy, M Berger, P Ford, T Feldman, A Mato, C Bejot, HC Fung, Leukemia & Lymphoma, 1/1/2014
• Impact of CD34 Cell Dose and Conditioning Regimens on Donor T-Cell and Myeloid Chimerism After an Alemtuzumab-Based In-Vivo T-Cell depleted Allogeneic Stem Cell Transp...
  Fung HC, ASBMT Tandem Meeting, Utah, 1/1/2013
• Impact of CD34 Cell Dose and Conditioning Regimens on Donor T-Cell and Myeloid Chimerism after an Alemtuzumab-Based In Vivo T-Cell Depleted Allogeneic Stem Cell Transp...
  Fung HC, Maciejewski J, Buckingham L, Alikhan M, Melinamani S, Karmali R, Rich E, Venugopal P, Gregory SA, Nathan S, Biology of Blood and Marrow Transplantation, 1/1/2013
• Stem Cell Mobilization Using the Combination of G-CSF (G) and Plerixafor (P) for Lymphoma Patients (pts) Can Overcome the Poor Prognostic Factors That Impact mobilizat...
  Nathan S, Maciejewski J, Rich E, Karmali R, Venugopal P, Gregory SA, Fung HC, Biology of Blood and Marrow Transplantation, 1/1/2013
• Transforming Growth Factor-Beta Gene Polymorphisms and Acute Graft-Versus-Host Disease
  Kanangat S, Basu S, Kurecovic I, Prod M, Maciejewski JJ, Nahan S, Fung HC, Journal of Clinical Oncology, 1/1/2013
• Despite the Use of the Combination of G-CSF and Plerixafor for Stem Cell Mobilization, One Third of the Patients with Lymphoma Were Still “Poor Mobilize” Using the Cri...
  Fung HC, ASBMT Tandem Meeting, 1/1/2012
• Engraftment Kinetics after Alemtuzumab-based Allogeneic Stem Cell Transplant: Full Donor T-Cell Chimerism did Not Predict for Acute GVHD and CMV reactivation
  Fung HC, ASH Annual Meeting, 1/1/2012
• Despite the Use of the Combination of G-CSF and Plerixafor for Stem Cell Mobilization, One Third of the Patients with Lymphoma Were Still “Poor Mobilizer” Using the Cr...
  Fung HC, Tornatta J, McLeod B, Nathan S, Maciejewski J, Ricch E, Karmali R, Jimenez A, Christopherson KW, Gregory SA, Biology of Blood and Marrow Transplantation, 1/1/2012
• Endothelial Progenitor Cell Mobilization in C57BL/6 Mice Following Treatment with Single Agent or Combination Neupogen (G-CSF), Plerixafor (AMD3100), and VEGF
  Frank RR, Jagan S, Paganessi LA, McNulty MA, Sumner DR, Fung HC, Gregory SA, Christopherson KW, Biology of Blood and Marrow Transplantation, 1/1/2012
• Effective Mobilization of Mesenchymal Stem Cells in C57BL/6 Mice Utilizing Single Agent Plerixafor (AMD3100) or in Combination with Neupogen (G-CF)
  Frank RR, Jagan S, Paganessi LA, McNulty MA, Sumner DR, Fung HC, Gregory SA, Christopherson KW, Biology of Blood and Marrow Transplantation, 1/1/2012
• Significant Adverse Effects Associated with Sirolimus/Tacrolimus GVHD Prophylaxis Regimen (Siro-tac) in Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) Patien...
  Nathan S, Maciejewski JJ, Rich ES, Gregory SA, Schultz K, Fung HC, Biology of Blood and Marrow Transplantation, 1/1/2012
• Blast Percentage Prior to Transplantation Is the Strongest Predictive Factor for Survival After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Patients with M...
  Jimenez AM, Rich ES, Nathan S, Maciejewski J, Shammo JM, Katz D, Braun E, Hashmi S, Fung HC, Biology of Blood and Marrow Transplantation, 1/1/2012
• Secondary Neutropenia (SN) After Autologous Hematopoietic Stem Cell Transplanation (AHSCT) in patients (pts) with Lymphoma
  Nathan S, Maciejewski JJ, Rich ES, Venugopal P, Chrisopherson KW, Gregory SA, Fung HC, J Clin Oncol, 1/1/2012
• Join now to see all

Lectures

• Reduced Intensity Allogeneic Stem Cell Transplantation for Patient > 60 years old 
  Chicago, IL - 1/1/2003
• Autologous Hematopoietic Cell Transplantation for Patients with Chemo-Refractory Hodgkin’s Lymphoma 
  San Diego, CA - 1/1/2003
• A New Preparative Regimen for Older Patients with Aggressive CD-20 Positive B-cell Lymphoma Utilizing standard Dose Zevalin Combined with High Dose BEAM Followed by A... 
  San Diego, CA - 1/1/2003
• Tandem Autologous Stem Cell Transplantation for Patient with Primary Progressive or Poor-Risk recurrent Hodgkin’s Lymphoma 
  Orlando, FL - 1/1/2002
• Allogeneic Stem Cell Transplantation for Patients with Primary Refractory AML: Impact o Cytogenetic Risk Group in the Transplant Outcome 
  Orlando, FL - 1/1/2001
• Long-Term Follow-Up Report of Allogeneic bone Marrow Transplantation for Patients with Acute Leukemia in First Complete Remission Utilizing Fractionated Total Body Irr... 
  Atlanta, GA - 1/1/1999
• Allogeneic Bone Marrow Transplantation (BMT) for high-Risk ALL in First Remission 
  New Orleans, LA - 1/1/1999
• Evaluation of Prognostic Factors in Patients with Hodgkin’s Disease in First Relapse treated by Autologous Stem Cell Transplantation 
  San Diego, CA - 1/1/1997
• Allogeneic Bone Marrow Transplantation for Adults with Primary MDS Evaluation of Prognostic actors 
  Orlando, FL - 1/1/1996
• Intensive Therapy with Autografting for Adults with Poor Prognosis Germ Cell Tumors 
  Montreal - 1/1/1995
• Allogeneic Bone Marrow Transplantation for Patients with Acute Leukemia for Whom Primary Therapy Failed to Bring About Complete Remission 
  Montreal - 1/1/1995
• Intensive Therapy with Autologous Bone Marrow Transplantation for Adults with High-Grade 
  Keystone, CO - 1/1/1995
• Allogeneic Bone Marrow Transplantation for Adults with Myelodysplastic Syndrome 
  Los Angeles, CA - 1/1/1995
• Join now to see all